Navigation Links
Renal Research Institute Announces Scientific Presentations at the American Society of Nephrology Kidney Week
Date:10/31/2011

NEW YORK, Oct. 31, 2011 /PRNewswire/ -- At the American Society of Nephrology's (ASN) Kidney Week 2011, Renal Research Institute, LLC (RRI) is presenting research results from studies involving dialysis treatment, patient care and outcomes. RRI is dedicated to advancing therapy options for dialysis patients to provide the highest caliber of care based on advanced clinical technology. ASN's Kidney Week 2011 takes place Nov. 8-13 in Philadelphia, PA. It is the largest scientific gathering of kidney disease experts worldwide and organizers expect more than 13,000 attendees among them more than 10,000 scientists and clinicians.  

A selection of RRI research being presented this year includes:

  • Declining Interdialytic Weight Gain in Chronic HD Patients: An Ominous Sign? Results of an International Study. Adrian Marcos Guinsburg, MD, Cristina Marelli, MD, Adam Tashman, Michael Etter, MD, PhD, Daniele Marcelli, MD, Gero D. von Gersdorff, MD, Mathias Schaller, Yuedong Wang, PhD, Nathan W. Levin, MD, Peter Kotanko, MD and Len A. Usvyat.

  • Lower Dialysate Na+ Impacts Weight Gain And Fluid Overload Hospitalizations. Eduardo K. Lacson, MD, John Rogus, PhD, Peter Kotanko, MD, Nathan W. Levin, MD and Raymond M. Hakim, MD, PhD

  • Trends in Serum Na+ Levels Relate to Mortality in Incident HD Patients. Jochen G. Raimann, MD, Len A. Usvyat, Jeroen Kooman, MD, Frank van der Sande, MD, PhD, Stephan Thijssen, MD, Peter Kotanko, MD, Nathan W. Levin, MD.

  • Independent Validation of a Versatile Citrate Dialysis Model. Stephan Thijssen, MD, Len A. Usvyat, Jeffrey J. Sands, MD, Nathan W. Levin, MD, Peter Kotanko, MD and Jose A. Diaz-Buxo, MD

  • Red Blood Cell Life Span is Associated with Hemoglobin Variability in Chronic Hemodialysis Patients. Yanna Dou, MD, Anja Kruse, MD, Georges Ouellet, MD, Stephan Thijssen, MD, Nathan W. Levin, MD and Peter Kotanko, MD.

RRI will share their newest scientific findings in a total of over two dozen presentations at this year's ASN Kidney Week. Kidney Week 2011, the largest nephrology meeting worldwide, will provide a forum to discuss the latest findings in renal research and engage in educational sessions related to advances in the care of patients with kidney and related disorders. RRI contributes research to ASN each year on kidney disease, its related complications and treatment options, to further the advancement of kidney care quality and patient outcomes.

Founded in 1966, the American Society of Nephrology (ASN) is the world's largest professional society devoted to the study of kidney disease. Comprised of 11,000 physicians and scientists, ASN continues to promote expert patient care, to advance medical research, and to educate the renal community. ASN also informs policymakers about issues of importance to kidney doctors and their patients. ASN funds research, and through its world-renowned meetings and first-class publications, disseminates information and educational tools that empower physicians.

About Renal Research Institute

Formed in early 1997, Renal Research Institute embodies scientific commitment to better kidney care. RRI is a research collaboration between Fresenius Medical Care and New York's Beth Israel Medical Center with a goal to produce measurable improvements in patient outcomes, building on clinical nephrology and evaluating and applying new technology to enhance the quality of patient care. Through its collaborative relationships with dialysis facilities and strong ties to academic research institutions, RRI is able to enhance the spectrum of comprehensive renal services by advancing peritoneal and hemodialysis therapies through clinical research and the application of practice guidelines and new technology. This synergy with university partners, industry, and dialysis clinics is the first of its kind in the field of kidney disease. For more information, please visit www.renalresearch.com.


'/>"/>
SOURCE Renal Research Institute, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. PLC Systems RenalGuard® to be Featured in Chronic Kidney Disease and Contrast Nephropathy Session at TCT 2011
2. PLC Systems Receives FDA Approval to Commence Pivotal Study of RenalGuard in the U.S.
3. PLC Systems Signs ACIST Medical Systems, to Distribute RenalGuard® in France and Germany
4. PLC Receives Two Additional U.S. Patents and First Japanese Patent For Its RenalGuard® Technology
5. Hospira Announces Positive Results From Phase I U.S. Clinical Trial of Biosimilar Erythropoietin in Renal Patients
6. REMEDIAL II Trial of PLCs RenalGuard® Article Published in Circulation
7. Galil Medical Announces Reimbursement for Small Renal Cancer Cryoablation in Japan
8. B. Braun Renal Therapies Division Announces Availability of Advanced Apheresis Therapy System
9. JHP Pharmaceuticals Launches New Multipack Presentations of Adrenalin®, Coly-Mycin® M and Pitocin®
10. PLC Ramps Up for U.S. Clinical Trial of RenalGuard®
11. Argos Therapeutics Arcelis™ Immunotherapy for the Treatment of Renal Cell Carcinoma (RCC) in Combination With Sunitinib Demonstrates Strong Immunologic Response That Correlates to Improved Clinical Outcomes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... 28, 2017 RXi Pharmaceuticals Corporation (NASDAQ: ... that address significant unmet medical needs, today announced ... Japan Patent Office (JPO) for the composition of ... (CTGF) for the treatment or prevention of fibrotic ... and proliferative retinopathy (Japanese Patent #: 6060071).  This ...
(Date:3/28/2017)... , March 28, 2017 ... research with Cambridge ... Consortium   The Milner Therapeutics Institute today announces ... Elysium Health has committed significant investment for collaborative projects with ... next four years. This is the first major research investment ...
(Date:3/27/2017)... TEL-AVIV, Israel , March 27, 2017 /PRNewswire/ ... TASE: THXBY), a specialty clinical-stage pharmaceutical company specializing in the ... of its public offering in the ... Shares (ADSs), each ADS representing 40 ordinary shares ... per ADS. In addition, Therapix has granted the ...
Breaking Medicine Technology:
(Date:3/28/2017)... Georgia (PRWEB) , ... March 28, 2017 , ... ... to its award-winning team. Ruel Williamson brings his extensive knowledge of appraisals, property ... a leader in the real estate valuation industry for more than 40 years. ...
(Date:3/28/2017)... Seattle, WA (PRWEB) , ... March 28, 2017 ... ... reach a 22% share of all holidays (IBT World Travel Trends Report). As ... physically challenging, include a range in temperatures, and prolonged sun exposure. In response, ...
(Date:3/28/2017)... ... 28, 2017 , ... Z-Medica, LLC, a leading developer and ... (UPMC) will acquire QuikClot® Bleeding Control Kits® (BCK) to equip up to 1,000 ... efforts by the American College of Surgeons, U.S. Department of Defense, Department of ...
(Date:3/28/2017)... ... 28, 2017 , ... Award-winning medical group Allied Anesthesia today ... board chair for Orange County health care system CalOptima Friday. CalOptima announced its ... chair Mark Refowitz’s term, which runs through June 30 of this year, until ...
(Date:3/28/2017)... , ... March 28, 2017 , ... ... plans work, the Self-Funding Success website has recently developed and published an informational ... Plans ” was created based on common inquiries the site’s team of third ...
Breaking Medicine News(10 mins):